differences in response rates between crizotinib and each type of chemotherapy were significant (P<0.001).At the time of data cutoff, 96 deaths had oc- curred in the intention-to-treat population — 49 (28%) in the crizotinib group and 47 (27%) in the chemotherapy group — representing 40% ofthe total number of events required for the final analysis of overall survival. The median overall survival was 20.3 months (95% CI, 18.1 to not reached) with crizotinib and 22.8 months (95% CI, 18.6 to not reached) with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54) (Fig. S4 in the Supple- mentary Appendix). Of the 174 patients who were randomly assigned to chemotherapy, 112 (64%) subsequently received crizotinib outside the study; 34 patients (20%) discontinued che- motherapy but did not receive crizotinib, includ- ing 13 patients who died either while receiving chemotherapy or before starting follow-up ther- apy (Table S2 in the Supplementary Appendix).A total of 85 patients (49%) in the crizotinib group and 28 patients (16%) in the chemothera- py group were still receiving the study treatment at the time of data cutoff. More patients in the crizotinib group than in the chemotherapy group continued treatment beyond RECIST-defined pro- gression of disease (58 vs. 17), and the duration of such therapy was longer with crizotinib than with chemotherapy (median, 15.9 weeks [range, 2.9 to 73.4] vs. 6.9 weeks [range, 6.0 to 42.0]).
การแปล กรุณารอสักครู่..